Total submissions: 4
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV003120621 | SCV003796155 | likely benign | Spastic paraplegia | 2024-10-07 | criteria provided, single submitter | clinical testing | |
| Fulgent Genetics, |
RCV002495862 | SCV002794216 | uncertain significance | MASA syndrome; X-linked complicated corpus callosum dysgenesis; X-linked hydrocephalus syndrome | 2022-02-01 | criteria provided, single submitter | clinical testing | |
| Ambry Genetics | RCV002359156 | SCV002622900 | uncertain significance | Inborn genetic diseases | 2019-04-03 | criteria provided, single submitter | clinical testing | The p.R129W variant (also known as c.385C>T), located in coding exon 4 of the L1CAM gene, results from a C to T substitution at nucleotide position 385. The arginine at codon 129 is replaced by tryptophan, an amino acid with dissimilar properties. This amino acid position is poorly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
| Ce |
RCV001532221 | SCV001747674 | uncertain significance | not provided | 2021-06-01 | criteria provided, single submitter | clinical testing |